The 2026 Alzheimer's Association International Conference takes place July 12–15 in London, and BrainCheck will be presenting three accepted poster abstracts. Each study addresses a different dimension of the same clinical challenge: developing cognitive care tools that meet rigorous validation standards, demonstrate outcomes in real patient populations, and scale across diverse population settings.
The Montreal Cognitive Assessment remains one of the most widely used instruments for identifying mild cognitive impairment and early signs of dementia in clinical practice. Establishing score equivalence and diagnostic agreement between the MoCA and BrainCheck Assess was a necessary step in supporting the clinical validity of a digital alternative.
This study pooled data from 176 older adults across multiple clinical sites and examined the psychometric relationship between the two instruments. BrainCheck Assess and MoCA scores showed a strong correlation (r = 0.80), and ROC analyses demonstrated good discriminative performance across normal cognition, mild cognitive impairment, and dementia classifications. Score-mapping functions were derived to allow reliable translation of results between instruments.
For clinicians who have relied on the MoCA as a screening standard, these findings provide a basis for interpreting BrainCheck Assess results with comparable confidence, particularly in settings where paper-based administration is logistically difficult or inconsistent.
Psychometric validation establishes what a tool can do under controlled conditions. Understanding what it does in routine clinical practice requires a different kind of evidence.
This retrospective analysis examined de-identified data from 2,488 patients aged 50 and older who completed two or three BrainCheck Plan visits across multiple clinical practices between 2022 and 2025. Using linear mixed-effects models, the study evaluated changes in neuropsychiatric symptoms, functional measures, and caregiver outcomes over time.
Patients showed statistically significant annual reductions in anxiety as measured by the GAD-7 and depressive symptoms as measured by the Geriatric Depression Scale. Improvements were also observed in daily functioning as measured by the Katz Index. Caregiver outcomes followed a similar pattern, with significant annual reductions in both depressive symptoms and caregiver stress.
The dataset reflects the complexity of real-world dementia care, with patients and caregivers seen across varied clinical environments and practice types. The consistency of outcomes across that population is meaningful from a health services standpoint.
Cognitive screening rates remain low across many European healthcare systems, shaped by time constraints, limited specialist access, and a lack of standardized tools that function across languages and cultural contexts. This study, conducted as part of the international PREDICTOM initiative, examined the feasibility of translating and culturally adapting BrainCheck Assess for deployment across five European countries.
The platform was translated into Norwegian, Dutch, Spanish, German, and French by certified translators, then reviewed by native speakers aged 50 and older for linguistic accuracy, cultural appropriateness, and usability for older adult populations. Particular attention was given to the recognition assessment component, which required careful word-level review across each language.
Among the 416 participants who completed testing across five countries, 98.3% finished the full assessment battery. The high completion rate across varied populations and device types supports the feasibility of broad international deployment for early dementia detection.
If you are attending AAIC 2026, our posters are scheduled as follows:
July 12 — Evaluating the Effectiveness of Cognitive Care Planning in Patients and Caregivers Using Real-World Data | Session P1–12 | Exhibit Hall
July 13 — Psychometric Validation of BrainCheck Assess Against the MoCA for Detecting Cognitive Impairment in Older Adults | Session P2–06 | Exhibit Hall
July 14 — Translation and Adaptation of BrainCheck Assess for Use in European Populations | Session P3–06 | Exhibit Hall